Bausch Health's (BHC) Canada unit said Wednesday that it has signed a letter of intent with the pan-Canadian Pharmaceutical Alliance for public drug plan coverage in Canada for its acne vulgaris treatment Cabtreo.
The company said the agreement allows Bausch Health Canada to finalize the listing of Cabtreo under individual government drug plans across Canada, including federal, provincial and territorial programs.
No financial terms of the agreement were disclosed.
Cabtreo has been approved by Health Canada as a triple-combination topical acne treatment, the company said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.